Core Viewpoint - XTL Biopharmaceuticals Ltd. has received a notification from Nasdaq indicating that it does not meet the minimum bid price requirement of $1 per share for continued listing [1][2]. Group 1: Nasdaq Notification Details - The notification does not lead to immediate delisting, and the company's American Depositary Shares (ADSs) will continue to trade under the symbol "XTLB" [2]. - XTL has a compliance period of 180 calendar days, until June 22, 2026, to regain compliance by achieving a closing bid price of at least $1 for a minimum of ten consecutive business days [3]. - If compliance is not regained, XTL may qualify for additional time by meeting other listing requirements and may need to consider a reverse stock split [4]. Group 2: Company's Response and Future Plans - The company is currently evaluating options to regain compliance and intends to make reasonable efforts to meet Nasdaq's continued listing requirements [5]. - XTL holds 100% of The Social Proxy Ltd., a web data company, and has sublicensed an IP portfolio for the treatment of Lupus disease [6].